Twenty-two percent of pregnant women are seropositive for herpes simplex virus1 and 2% of susceptible pregnant women acquire a primary herpes simplex virus infection.2 Data on the use of acyclovir and valacyclovir to treat infected women are extremely scarce. The Slone Epidemiology Center, Boston, Massachusetts, statistics on normal pregnancies indicate that approximately 2 per 1000 pregnancies are exposed to each drug during organogenesis (A. Mitchell and C. Louik, Slone Epidemiology Center at Boston University, written communication, July 14, 2010). Thus, each year in the United States approximately 15 000 conceptuses are potentially exposed to these drugs, yet little information is available on their teratogenicity. Until now, only relatively small studies had evaluated the potential teratogenicity of acyclovir and related drugs.3- 6 Although these studies generally showed no teratogenic effects, they were underpowered to answer the question definitively.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.